Back to results
US 10,881,677 B2Granted
Composition for modulating IRAK1
AssigneeAgency for Science, Technology and Research
InventorsQiang Yu, Zhen Ning Wee
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAgency for Science, Technology and Research
InventorsQiang Yu, Zhen Ning Wee
Estimating the term…
The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.
A therapeutic method for a patient with triple negative breast cancer and resistant to paclitaxel therapy, the method comprising:
A method for treating a patient with triple negative breast cancer and resistant to paclitaxel therapy who has an elevated level of interleukin 1 receptor associated kinase 1 (IRAK1) protein relative to normal levels in healthy individuals as determined by measuring the level of IRAK1 protein in a sample obtained from the patient, the method comprising administering an inhibitor of IRAK1 activity to the patient, wherein the inhibitor of IRAK1 activity is a ginsenoside.
Dependencies are inferred from the claim text.